{"id":"https://openalex.org/W3132404807","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1734.1734","title":"Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia","display_name":"Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W3132404807","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1734.1734","mag":"3132404807"},"language":"en","primary_location":{"id":"mag:3132404807","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1734.1734","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1734/79483/Efficacy-Results-of-a-Phase-2-Trial-Evaluating","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017380326","display_name":"Benjamin L. Lampson","orcid":"https://orcid.org/0000-0002-6033-3363","observed_orcids":["https://orcid.org/0000-0002-6033-3363"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin L. Lampson","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0002-6033-3363","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045479163","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook T. Kim","raw_affiliation_strings":["Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-4889-6849","affiliations":[{"raw_affiliation_string":"Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0003-4529-2003","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002103749","display_name":"Jeremy S. Abramson","orcid":"https://orcid.org/0000-0001-8467-9257","observed_orcids":["https://orcid.org/0000-0001-8467-9257"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy S. Abramson","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":"https://orcid.org/0000-0001-8467-9257","affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037942629","display_name":"Arnold S. Freedman","orcid":"https://orcid.org/0000-0002-8227-8916","observed_orcids":["https://orcid.org/0000-0002-8227-8916"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arnold S. Freedman","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0002-8227-8916","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caron A. Jacobson","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0002-0180-0654","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0001-6098-1603","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028590331","display_name":"Robin Joyce","orcid":"https://orcid.org/0000-0002-7251-8082","observed_orcids":["https://orcid.org/0000-0002-7251-8082"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robin Joyce","raw_affiliation_strings":["Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-7251-8082","affiliations":[{"raw_affiliation_string":"Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon Arnason","raw_affiliation_strings":["Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-9038-7277","affiliations":[{"raw_affiliation_string":"Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010336471","display_name":"Laura Z. Rassenti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Z. Rassenti","raw_affiliation_strings":["Moores Cancer Center - University of California San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center - University of California San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["Moores Cancer Center - University of California San Diego, La Jolla, CA"],"raw_orcid":"https://orcid.org/0000-0002-0064-4549","affiliations":[{"raw_affiliation_string":"Moores Cancer Center - University of California San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101484442","display_name":"Samantha Huang","orcid":"https://orcid.org/0000-0003-0970-7355","observed_orcids":["https://orcid.org/0000-0003-0970-7355"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha Huang","raw_affiliation_strings":["Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-0970-7355","affiliations":[{"raw_affiliation_string":"Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029993254","display_name":"Joshua Alexander Fein","orcid":"https://orcid.org/0000-0001-5441-1516","observed_orcids":["https://orcid.org/0000-0001-5441-1516"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua Fein","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0001-5441-1516","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108748734","display_name":"John Hanna","orcid":"https://orcid.org/0009-0006-0428-3505","observed_orcids":["https://orcid.org/0009-0006-0428-3505"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Hanna","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009506175","display_name":"Stacey M. Fernandes","orcid":"https://orcid.org/0000-0002-5061-5199","observed_orcids":["https://orcid.org/0000-0002-5061-5199"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey M. Fernandes","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0002-5061-5199","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fisher","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0001-6915-8584","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,"],"raw_orcid":"https://orcid.org/0000-0003-2040-4961","affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.7703,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.71881215,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"130","issue":null,"first_page":"1734","last_page":"1734"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/idelalisib","display_name":"idelalisib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/previously-untreated-cll","display_name":"previously untreated CLL","score":0.7639999985694885},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.9049999713897705},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6690000295639038},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.8939999938011169},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.984000027179718},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.6919999718666077},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.5659999847412109},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.3370000123977661},{"id":"https://openalex.org/keywords/trial-discontinuation","display_name":"trial discontinuation","score":0.36000001430511475}],"concepts":[{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.9622626304626465},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.9020498394966125},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.778053879737854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6368768215179443},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5570371150970459},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.523172914981842},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.48144906759262085},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.47897839546203613},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.41273242235183716},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40437445044517517},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.18041247129440308}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3132404807","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1734.1734","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1734/79483/Efficacy-Results-of-a-Phase-2-Trial-Evaluating","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2598989869","https://openalex.org/W2463174815","https://openalex.org/W2594646846","https://openalex.org/W262475294","https://openalex.org/W2131078883","https://openalex.org/W2244500181","https://openalex.org/W2938268271","https://openalex.org/W2597890466","https://openalex.org/W63804436","https://openalex.org/W2556925907"],"abstract_inverted_index":{"Introduction":[0],":":[1,79,166,536],"Idelalisib":[2],"(idela)":[3],"is":[4,540,653,718],"a":[5,39,196,335,590,612,713],"selective":[6],"oral":[7],"inhibitor":[8],"of":[9,22,27,43,60,97,104,119,128,142,150,174,187,199,212,263,293,318,337,371,404,457,467,480,502,507,513,519,546,554,576,593,643,659,678,682,716,739,762,776,791,805,821,841,899,1031],"PI3K\u03b4":[10,683],"that,":[11],"when":[12],"combined":[13],"with":[14,47,53,62,94,239,249,255,431,662],"rituximab,":[15],"has":[16],"an":[17,491,529,736,759,773,788,802,818,838,896,997,1028],"overall":[18],"response":[19],"rate":[20,466],"(ORR)":[21],"70-80%":[23],"for":[24,83,334,352,442,542,573,623,656,693,709],"the":[25,120,465,543,558,562,574,687],"treatment":[26,81,351,545],"relapsed/refractory":[28],"(R/R)":[29],"CLL.":[30,54,353],"Given":[31],"this":[32,63,84,427,555],"efficacy":[33,68],"in":[34,45,50,135,146,155,210,320,426,433,557,626,636,672,686],"R/R":[35],"disease,":[36],"we":[37,65],"initiated":[38],"phase":[40,85],"2":[41,95,124,397,478],"trial":[42,132,157,271],"idela":[44,98,105,112,159,264,577],"combination":[46,108,129,556,575],"ofatumumab":[48],"(ofa)":[49],"treatment-naive":[51],"patients":[52,154,168,215,254,391,645],"We":[55],"previously":[56,421,571],"reported":[57,572],"high":[58],"rates":[59,141],"hepatotoxicity":[61,423],"combination;":[64],"now":[66],"report":[67],"and":[69,152,184,206,224,246,282,305,342,408,413,451,464,510,631,703,705],"safety":[70],"data":[71],"on":[72,615,735,758,772,787,801,817,837,895,1027],"all":[73,153,525],"enrolled":[74],"subjects.":[75,213],"Methods":[78],"The":[80,116,131,233,640],"regimen":[82],"2,":[86],"open-label,":[87],"multicenter,":[88],"single":[89],"arm,":[90],"investigator-initiated":[91],"study":[92,121],"began":[93],"months":[96,103,125,183,278],"monotherapy,":[99],"followed":[100,110],"by":[101,111],"six":[102],"+":[106,538,578],"ofa":[107,539],"therapy,":[109,582],"monotherapy":[113],"until":[114],"progression.":[115,389],"primary":[117],"endpoint":[118],"was":[122,133,179,189,236,276,285,356,361,469,564,568,586],"ORR":[123,235,563],"after":[126,331,411,589,675],"completion":[127],"therapy.":[130],"halted":[134],"March":[136],"2016":[137],"due":[138,265,386,394,489,649],"to":[139,266,379,387,395,415,490,528,611,619,632,650],"increased":[140],"infectious-disease":[143],"related":[144],"deaths":[145],"other":[147],"frontline":[148,559,581],"trials":[149,658],"idela,":[151],"our":[156],"ceased":[158,368],"at":[160,170],"that":[161],"time.":[162],"Results":[165],"Twenty-seven":[167],"received":[169,258],"least":[171],"one":[172],"dose":[173],"idela.":[175,679],"Median":[176,274,354],"follow-up":[177,594],"time":[178,614],"32.2":[180],"(range":[181,191,201,339],"13-35)":[182],"median":[185,197,336,566,584],"duration":[186,715],"therapy":[188,333,369,418,621,634,648,661,717],"8.1":[190],"0.3-20.6)":[192],"months.":[193],"Demographics":[194],"included":[195,477],"age":[198],"69":[200],"57-84)":[202],"years,":[203],"78%":[204],"men,":[205],"ECOG":[207,290],"status":[208,292],"0/1":[209],"100%":[211],"Five":[214],"(18.5%)":[216],"had":[217,222,227,326],"del17p/TP53":[218],"mutations,":[219],"4":[220],"(14.8%)":[221],"del11q,":[223],"13":[225],"(48%)":[226],"IGHV":[229,447],"unmutated":[231],"disease.":[232],"best":[234],"89%":[237],"(24/27)":[238],"1":[240,247,294,486,500,505,511],"CR":[241],"(3.7%),":[242],"22":[243],"PRs":[244],"(81.5%),":[245],"PR":[248],"lymphocytosis":[250],"(3.7%).":[251],"All":[252],"3":[253],"stable":[256],"disease":[257,388,450,668,710],"fewer":[259],"than":[260,570],"30":[261],"days":[262],"either":[267],"toxicity":[268,372],"(2)":[269],"or":[270,329,376,741,764,778,793,807,823,843,901,1033],"halt":[272],"(1).":[273],"PFS":[275,284,319,567,585,607],"22.9":[277],"(95%":[279,287,363],"CI:":[280,288,364],"17.4-29.9)":[281],"2-year":[283,359],"42%":[286],"23-60%).":[289],"performance":[291],"versus":[295],"0":[296],"(HR":[297,307],"3.33,":[298],"95%":[299,309],"CI":[300,310],"1.23-9.03,":[301],"p":[303,313],"=0.018)":[304],"del17p":[306],"4.37,":[308],"1.11-17.15,":[311],"=0.035)":[314],"were":[315,454,459,670],"significant":[316,549],"predictors":[317],"univariate":[321],"analysis.":[322],"Nine":[323],"subjects":[324,344,627,674,708],"(44%)":[325],"not":[327,347,357,587],"progressed":[328],"died":[330],"receiving":[332],"11":[338],"0.5-20)":[340],"months,":[341],"16":[343],"(59%)":[345],"have":[346],"required":[348],"any":[349],"subsequent":[350],"OS":[355,360],"reached;":[358],"92%":[362],"71-98%).":[365],"Subjects":[367],"because":[370],"(":[373,381],"n":[374,382],"=15)":[375],"regulatory":[377,651],"mandate":[378,652],"discontinue":[380],"=12);":[383],"none":[384],"stopped":[385,393],"Of":[390,666],"who":[392,628,646],"mandate,":[396],"(17%)":[398],"experienced":[399],"acute":[400],"tumor":[401],"flares":[402,669],"consisting":[403],"fevers,":[405],"enlarging":[406],"nodes,":[407],"rash":[409],"shortly":[410],"discontinuation":[412,677],"needed":[414],"start":[416],"alternative":[417],"rapidly.":[419],"As":[420],"reported,":[422],"remained":[424],"frequent":[425,620],"more":[428],"mature":[429],"analysis,":[430],"transaminitis":[432],"74%":[434],"(grade":[435,461,471],"\u22653,":[436,462,472],"52%).":[437],"Previously":[438],"identified":[439],"risk":[440],"factors":[441],"early":[443,630],"hepatotoxicity,":[444],"including":[445],"mutated":[449],"younger":[452],"age,":[453],"confirmed.":[455],"Rates":[456],"diarrhea/colitis":[458],"48%":[460],"15%)":[463],"pneumonitis":[468],"11%":[470],"3.7%).":[473],"Opportunistic":[474],"infections":[475],"(OIs)":[476],"cases":[479],"P":[482,497,521],"jirovecii":[483,498,522],"pneumonia,":[485,504],"brain":[487],"abscess":[488],"unknown":[492],"organism":[493],"(thought":[494],"likely":[495],"),":[499],"case":[501,506,512],"Aspergillus":[503],"cytomegalovirus":[508],"colitis,":[509],"herpes":[514],"simplex":[515],"virus":[516],"esophagitis.":[517],"Cases":[518],"infection":[524],"occurred":[526],"prior":[527],"amendment":[530],"requiring":[531],"prophylaxis.":[532],"Conclusions":[535],"Idela":[537],"effective":[541],"upfront":[544],"CLL,":[547],"but":[548],"toxicities":[550,698],"may":[551,608],"limit":[552],"development":[553],"setting.":[560],"While":[561],"high,":[565],"shorter":[569,606],"rituximab":[579],"as":[580,700],"where":[583],"reached":[588],"similar":[591],"length":[592],"(O9Brien":[595],"Blood":[597],"2015,":[599],"Thompson":[600],"Cancer":[602],"2016).":[604],"This":[605],"be":[609],"attributable":[610],"limited":[613,714],"treatment,":[616],"secondary":[617],"both":[618],"interruptions":[622],"adverse":[624],"events":[625],"discontinued":[629,647],"mandated":[633],"cessation":[635],"those":[637],"doing":[638],"well.":[639],"clinical":[641],"course":[642],"responding":[644],"potentially":[654],"informative":[655],"future":[657],"time-limited":[660],"novel":[663],"kinase":[664],"inhibitors.":[665],"note,":[667],"seen":[671],"some":[673],"abrupt":[676],"Future":[680],"studies":[681],"inhibitors,":[684],"particularly":[685],"frontline,":[688],"should":[689],"routinely":[690],"employ":[691],"prophylaxis":[692],"OIs,":[694],"systematically":[695],"investigate":[696],"key":[697],"such":[699],"hepatitis,":[701],"diarrhea/colitis,":[702],"pneumonitis,":[704],"closely":[706],"monitor":[707],"progression":[711],"if":[712],"investigated.":[719],"Disclosures":[721],"Davids:":[724],"Astra-Zeneca:":[727],"Consultancy;":[729,753,831,855,859,863,867,871,875,880,943,1042,1052,1057,1066,1070,1074,1086,1090,1094],"Janssen:":[731,1092],"Consultancy,":[733,747,770,815,835,930,937,950,979,985,990,1001,1008,1014,1046,1061,1079],"Membership":[734,757,771,786,800,816,836,894,1026],"entity9s":[737,760,774,789,803,819,839,897,1029],"Board":[738,761,775,790,804,820,840,898,1030],"Directors":[740,763,777,792,806,822,842,900,1032],"advisory":[742,765,779,794,808,824,844,902,1034],"committees;":[743,766,795],"Infinity:":[745,941],"Research":[748,781,810,826,846,885,910,915,920,925,931,938,951,957,962,974,992,1003,1009,1016,1047,1080],"Funding;":[749,782,811,827,911,916,921,926,932,939,952,958,963,975,993,1004,1010,1048,1081],"Merck:":[751],"Gilead:":[755,861,977,1044],"Pharmacyclics:":[768,1072],"committees,":[780,809,825,845],"InCyte:":[784],"TG":[797],"Therapeutics:":[798,883],"Abbvie:":[813,857],"Celgene:":[829,873,988,1088],"Genentech:":[833,865,1006],"Funding.":[847,886,1017],"Abramson:":[849],"Kite":[852,891],"Pharma:":[853,1055],"Novartis:":[869],"Seattle":[877,1022],"Genetics:":[878],"LAM":[882],"Jacobson:":[888],"Pharmaceuticals:":[892,1084],"committees.":[903,1035],"Armand:":[905],"Tensha:":[908],"Sequenta/Adaptive:":[913],"Roche:":[918,983],"Affimed:":[923],"Pfizer:":[928,1050],"Bristol-Myers":[934],"Squibb:":[935],"Merck":[945],"&":[946],"Co.,":[947],"Inc.:":[948,1024],"Sigma":[954],"Tau:":[955],"Otsuka:":[960],"Genmab:":[965],"Consultancy.":[967],"Kipps:":[969],"Oncternal:":[972],"Speakers":[980],"Bureau;":[981],"Honoraria;":[986,1062],"Honoraria,":[991,1002,1015],"Pharmacyclics":[995],"LLC,":[996],"AbbVie":[998],"Company:":[999],"AbbVie:":[1012,1059],"Fisher:":[1019],"Genetics":[1023],"Brown:":[1037],"Roche/Genentech:":[1040],"Astellas":[1054],"AstraZeneca:":[1064],"Redx:":[1068],"Sun":[1076],"BioPharma:":[1077],"Infinity":[1083],"Janssen":[1096],"Oncology:":[1097],"Honoraria.":[1099]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-03-01T00:00:00"}